- Home
- WDI vs ABCL Comparison
WDI vs ABCL Comparison
Compare WDI & ABCL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WDI
- ABCL
- Stock Information
- Founded
- WDI 2021
- ABCL 2012
- Country
- WDI United States
- ABCL Canada
- Employees
- WDI N/A
- ABCL N/A
- Industry
- WDI Trusts Except Educational Religious and Charitable
- ABCL Biotechnology: Pharmaceutical Preparations
- Sector
- WDI Finance
- ABCL Health Care
- Exchange
- WDI Nasdaq
- ABCL Nasdaq
- Market Cap
- WDI 753.0M
- ABCL 772.9M
- IPO Year
- WDI N/A
- ABCL 2020
- Fundamental
- Price
- WDI $14.81
- ABCL $3.45
- Analyst Decision
- WDI
- ABCL Strong Buy
- Analyst Count
- WDI 0
- ABCL 4
- Target Price
- WDI N/A
- ABCL $8.33
- AVG Volume (30 Days)
- WDI 192.6K
- ABCL 7.5M
- Earning Date
- WDI 01-01-0001
- ABCL 08-05-2025
- Dividend Yield
- WDI 11.80%
- ABCL N/A
- EPS Growth
- WDI N/A
- ABCL N/A
- EPS
- WDI 1.12
- ABCL N/A
- Revenue
- WDI N/A
- ABCL $23,114,000.00
- Revenue This Year
- WDI N/A
- ABCL N/A
- Revenue Next Year
- WDI N/A
- ABCL $67.99
- P/E Ratio
- WDI $12.82
- ABCL N/A
- Revenue Growth
- WDI N/A
- ABCL N/A
- 52 Week Low
- WDI $12.16
- ABCL $1.89
- 52 Week High
- WDI $14.69
- ABCL $4.09
- Technical
- Relative Strength Index (RSI)
- WDI 53.77
- ABCL 71.02
- Support Level
- WDI $14.53
- ABCL $3.52
- Resistance Level
- WDI $14.75
- ABCL $4.09
- Average True Range (ATR)
- WDI 0.11
- ABCL 0.31
- MACD
- WDI -0.04
- ABCL 0.04
- Stochastic Oscillator
- WDI 47.56
- ABCL 70.43
About WDI Western Asset Diversified Income Fund of Beneficial Interest
Western Asset Diversified Income Fund is a newly-organized, diversified, closed-end management investment company. The fund's primary investment objective is to seek high current income.
About ABCL AbCellera Biologics Inc.
AbCellera Biologics Inc is an antibody discovery and development engine that's specifically designed to address the barriers of conventional discovery, finding the optimal clinical candidate with greater precision and speed, getting to the clinic and patients sooner. With the integrated AbCellera platform, the company's experts search a wide range of diverse antibodies to select the effective and developable leads fast and set partners up for enduring success. The company has extensive experience forging partnerships with emerging biotechs and pharmaceutical companies. AbCellera leverages proprietary hardware, software, and tools along with the latest data science, to operate as strategic partners and help develop optimized solutions faster for any program.